Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer and Eyetech Joint Filing Accepted in EU; Action Pending Elsewhere

By Pharmaceutical Processing | September 21, 2004

NEW YORK, NY (Sept. 20, 2004) — Pfizer Inc. and Eyetech Pharmaceuticals, Inc. announced this week that the European Medicines Agency (EMEA) has accepted the filing of their marketing authorization application for Macugen (pegaptanib sodium injection), the first in a new class of medicines for neovascular age-related macular degeneration (AMD).

The companies also announced that they have completed the filing of a new drug application for Macugen in Canada, where it has been given priority review, and have begun clinical trials with the medicine in Japan.

The AMD Alliance International estimates that 500,000 new cases of neovascular AMD are diagnosed annually worldwide. The disease is said to be the leading cause of severe vision loss in patients over 50 years of age in the developed world.

Under the terms of the Pfizer/Eyetech collaboration agreement, Pfizer will market Macugen for the prevention and treatment of diseases of the eye and related conditions outside the United States, and pay Eyetech a royalty on net sales. The two companies will co-market the drug in the United States. Macugen currently is under priority review with the U.S. Food & Drug Administration.

Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals.

Eyetech Pharmaceuticals is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye.

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards